Additional Value of New Molecular Imaging Tracers in the Detection of Recurrent/Residual Disease in Patients with Neuroendocrine Tumors Abstract #651

Introduction: Recent studies have proposed new molecular imaging tracers, such as 18F-DOPA and 68Ga-DOTANOC, for the detection of recurrent/residual neuroendocrine tumors (NET) in case of negative conventional imaging modalities.
Aim(s): To evaluate sensitivity of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in the detection of residual/recurrent NET.
Materials and methods: Fifteen patients with NET were enrolled. All had biochemical evidence of recurrent/residual disease, not evident at conventional imaging techniques. Six patients had medullary thyroid carcinoma (MTC) with post-surgical persistence of increased calcitonin, two had a suspicion of pheocromocytoma, five had SDHB and SDHD mutation gene underlying multiple/malignant polyglandular (PGL) syndrome and two had MEN-1. All patients underwent 18F-DOPA (13 cases) or 68Ga-DOTANOC PET/CT (two cases).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Andrea Lania

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2854 A Meta-Analysis of the Accuracy of a Neuroendocrine Tumor mRNA Genomic Biomarker (NETest) in Blood
Introduction: The lack of an accurate blood biomarker in neuroendocrine tumor (NET) disease impedes effective management.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Öberg K, Califano A, Strosberg J, Ma S, ...
#2985 Peptide Receptor Radionuclide Therapy (PRRT) Outcome Prediction in Neuroendocrine Tumors (NET): Could Radiomic Features Analysis of 68Ga-DOTATOC PET/CT Have a Roll?
Introduction: The PRRT is an effective treatment for NET, but the selection of a good candidate is a very important step.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Virginia Liberini
#2926 O-Positive Blood Group Is Associated with Prolonged Recurrence-Free Survival Following Pancreatic Neuroendocrine Tumor (PanNET) Curative-Intent Surgical Resection
Introduction: The ABO blood group may influence the development and progression of cancer. In particular, the prognosis of pancreatic adenocarcinoma is better in patients with blood group O. This has not been extensively explored in PanNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Louis de Mestier
#2701 Assessing the Gaps in Experience and Knowledge of Australian Primary Health Care Professionals (GPs), in Treating and Caring for the Increasing Number of Australian Neuroendocrine Tumour (NET) Patients
Introduction: Conservatively,the incidence of NETs is 7 / 000' p.a, however,the prevalence of patients living with NETs is higher,40/000',making it the 2nd most common GI malignancy after colorectal cancer.Patients are living longer,however,with impaired quality of life.Management of debilitating symptoms such as diarrhoea,fatigue,anxiety,and flushing are complex and heterogenous.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Simone Leyden
Authors: Leyden S, Cummins M, Wakelin K, ...
#2757 Effectiveness of Lanreotide 120 mg (LAN) in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumours (panNET) in Routine Clinical Practice
Introduction: PanNETs are the second most common type of tumour of the pancreas. Most patients have metastatic disease at diagnosis with median survival ranges from 2 to 5 years. Somatostatin analogs (SSAs) control symptoms and reduce tumour growth in panNET. In the panNET subgroup of the CLARINET study, lanreotide autogel 120 mg reduced the relative risk of progression or death by more than 40% compared with placebo at week 96.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: doctor Guillermo de La Cruz